GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Forward PE Ratio

Can Fite Biofarma (Can Fite Biofarma) Forward PE Ratio : 0.00 (As of Apr. 26, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Can Fite Biofarma Forward PE Ratio?

Can Fite Biofarma's Forward PE Ratio for today is 0.00.

Can Fite Biofarma's PE Ratio without NRI for today is 0.00.

Can Fite Biofarma's PE Ratio for today is 0.00.


Can Fite Biofarma Forward PE Ratio Historical Data

The historical data trend for Can Fite Biofarma's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Forward PE Ratio Chart

Can Fite Biofarma Annual Data
Trend 2023-05
Forward PE Ratio
2.55

Can Fite Biofarma Quarterly Data
2023-03
Forward PE Ratio 2.61

Competitive Comparison of Can Fite Biofarma's Forward PE Ratio

For the Biotechnology subindustry, Can Fite Biofarma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biofarma's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Forward PE Ratio falls into.



Can Fite Biofarma Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Can Fite Biofarma  (AMEX:CANF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Can Fite Biofarma Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Can Fite Biofarma (Can Fite Biofarma) Business Description

Traded in Other Exchanges
Address
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (Can Fite Biofarma) Headlines

From GuruFocus

Can-Fite BioPharma Announces $6 Million Registered Direct Offering

By Marketwired Marketwired 05-20-2019